Alcohol and substance abuse in solid-organ transplant recipients

Transplantation

Volumn 96, Issue 12, 2013, Pages 1015-1024

  Parker, Richard ^a,b   Armstrong, Matthew J ^a,b   Corbett, Chris ^a,b   Day, Edward J ^a   Neuberger, James M ^b,c  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^c NHS BLOOD AND TRANSPLANT   (United Kingdom)

Author keywords

Alcohol; Drugs; Substance abuse; Transplantation

Indexed keywords

ACAMPROSATE; ALCOHOL; AMPHETAMINE; BUPRENORPHINE; CANNABINOID DERIVATIVE; CANNABIS; CARBOHYDRATE DEFICIENT TRANSFERRIN; COCAINE; CYTOCHROME P450 2E1; GAMMA GLUTAMYLTRANSFERASE; ILLICIT DRUG; IMMUNOSUPPRESSIVE AGENT; METHADONE; NALTREXONE; OPIATE DERIVATIVE;

ACUTE GRAFT REJECTION; ALCOHOL ABSTINENCE; ALCOHOL ABUSE; ALCOHOL CONSUMPTION; ALCOHOL INDUCED LIVER DISEASE; ALCOHOLISM; ANXIETY DISORDER; ATHEROSCLEROSIS; BIOCHEMISTRY; BLOOD EXAMINATION; BRAIN HEMORRHAGE; CARDIOVASCULAR DISEASE; COGNITIVE THERAPY; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DISEASE ASSOCIATION; DRUG MISUSE; DSM-IV; FATTY LIVER; GRAFT RECIPIENT; HEART FAILURE; HEART MUSCLE ISCHEMIA; HEART TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; HYPERTENSION; ICD-10; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INTRAVENOUS DRUG ABUSE; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LIFESTYLE MODIFICATION; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FAILURE; LIVER TRANSPLANTATION; LUNG DISEASE; LUNG EDEMA; LUNG TRANSPLANTATION; MENTAL DISEASE; OPIATE ADDICTION; ORGAN TRANSPLANTATION; PANCREATITIS; PANIC; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PSYCHOSIS; RELAPSE; REVIEW; RHABDOMYOLYSIS; SCREENING TEST; SELF HELP; SELF REPORT; SENSITIVITY AND SPECIFICITY; SEX DIFFERENCE; SMOKING; SOILD ORGAN TRANSPLANTATION; SUBSTANCE ABUSE; SURVIVAL TIME; SYSTEMATIC REVIEW; TOBACCO USE; TREATMENT CONTRAINDICATION;

EID: 84891626856     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31829f7579     Document Type: Review

References (118)

1. Neuberger J, Adams D, MacMaster P, et al. Assessing priorities for allocation of donor liver grafts: survey of public and clinicians. BMJ 1998; 317: 172.
2. BBC News. http://news.bbc.co.uk/1/hi/health/7136005.stm. Accessed 15 August 2012.
3. Telegraph Newspaper. http://www.telegraph.co.uk/news/uknews/1572091/ Organs-from-drug-addicts-used-in-transplants.html#. Accessed 13 August 2012.
4. Kotlyar DS, Burke A, Campbell MS, et al. A critical review of candidacy for orthotopic liver transplantation in alcoholic liver disease. Am J Gastroenterol 2008; 103: 734.
5. Sandhu GS, Khattak M, Woodward RS, et al. Impact of substance abuse on access to renal transplantation. Transplantation 2011; 91: 86.
6. Sharkey K, Gillam L. Should patients with self-inflicted illness receive lower priority in access to healthcare resources? Mapping out the debate. J Med Ethics 2010; 36: 661.
7. Kluge EH. Drawing the ethical line between organ transplantation and lifestyle abuse. CMAJ 1994; 150: 745.
8. Glannon W. Responsibility, alcoholism, and liver transplantation. J Med Philos 1998; 23: 31.
9. Martens W. Do alcoholic liver transplantation candidates merit lower medical priority than non-alcoholic candidates? Transpl Int 2001; 14: 170.
10. Seth D, Haber PS, Syn WK, et al. Pathogenesis of alcohol-induced liver disease: classical concepts and recent advances. J Gastroenterol Hepatol 2011; 26: 1089.
11. Ho D. When good organs go to bad people. Bioethics 2008; 22: 77.
12. Strengthening the Reporting of Observational Studies in EpidemiologyVSTROBE checklist. http://www.strobe-statement. org/index.php?id= available-checklists. Accessed 23 March 2013.
13. Corbett C, Armstrong MJ, Neuberger J. Tobacco smoking and solid organ transplantation. Transplantation 2012; 94: 979.
14. International Statistical Classification of Diseases and Related Health Problems, Tenth Revision, 1990.
15. American Psychiatric Association. Diagnostic and Statistical Manual IV (DSM-IV), 1994.
16. O'Brien C. Addiction and dependence in DSM-V. Addiction 2011; 106: 866.
17. Room R, Babor T, Rehm J. Alcohol and public health. Lancet 2005; 365: 519.
18. Hall W, Degenhardt L. Adverse health effects of non-medical cannabis use. Lancet 2009; 374: 1383.
19. Taylor DR, Poulton R, Moffitt TE, et al. The respiratory effects of cannabis dependence in young adults. Addiction 2000; 95: 1669.
20. Hancox RJ, Poulton R, Ely M, et al. Effects of cannabis on lung function: a population-based cohort study. Eur Respir J 2010; 35: 42.
21. Vupputuri S, Batuman V, Muntner P, et al. The risk for mild kidney function decline associated with illicit drug use among hypertensive men. Am J Kidney Dis 2004; 43: 629.
22. Crowe AV, Howse M, Bell GM, et al. Substance abuse and the kidney. QJM 2000; 93: 147.
23. Shapiro GK, Buckley-Hunter L. What every adolescent needs to know: cannabis can cause psychosis. J Psychosom Res 2010; 69: 533.
24. Afonso L, Mohammad T, Thatai D. Crack whips the heart: a review of the cardiovascular toxicity of cocaine. Am J Cardiol 2007; 100: 1040.
25. Hong R, Matsuyama E, Nur K. Cardiomyopathy associated with the smoking of crystal methamphetamine. JAMA 1991; 265: 1152.
26. Rogers G, Elston J, Garside R, et al. The harmful health effects of recreational ecstasy: a systematic review of observational evidence. Health Technol Assess 2009; 13: 3.
27. Green AR, Mechan AO, Elliott JM, et al. The pharmacology and clinical pharmacology of 3, 4-methylenedioxymethamphetamine (MDMA, "ecstasy"). Pharmacol Rev 2003; 55: 463.
28. Rehm J, Room R, Graham K, et al. The relationship of average volume of alcohol consumption and patterns of drinking to burden of disease: an overview. Addiction 2003; 98: 1209.
29. World Health Organisation Substance Abuse Department. Global Status Report: Alcohol Policy. World Health Organization; 2004.
30. Hasin DS, Stinson FS, Ogburn E, et al. Prevalence, correlates, disability, and comorbidity of DSM-IV alcohol abuse and dependence in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry 2007; 64: 830.
31. Doll R, Peto R, Hall E, et al. Mortality in relation to consumption of alcohol: 13 years' observations on male British doctors. BMJ 1994; 309: 911.
32. Reynolds K, Lewis LB, Nolen JDL, et al. Alcohol consumption and risk of stroke. JAMA 2003; 289: 579.
33. Hart CL,Morrison DS, Batty GD, et al. Effect of body mass index and alcohol consumption on liver disease: analysis of data from two prospective cohort studies. BMJ 2010; 340.
34. International Centre for Alcohol Policy. http://www.icap.org/table/ Internationaldrinkingguidelines. Accessed 29 August 2012.
35. UnitedNationsOffice for Drugs and Crime.WorldDrugReport 2011, 2011.
36. National Institute for Drug Abuse. Topics in Brief: Prescription Drug Abuse, 2011.
37. Compton WM, Volkow ND. Major increases in opioid analgesic abuse in the United States: concerns and strategies. Drug Alcohol Depend 2006; 81: 103.
38. Bunzel B, Laederach-Hofmann K. Solid organ transplantation: are there predictors for posttransplant noncompliance? A literature overview. Transplantation 2000; 70: 711.
39. Murray KF, Carithers RL Jr. AASLD practice guidelines: evaluation of the patient for liver transplantation. Hepatology 2005; 41: 1407.
40. Starzl TE, Van Thiel D, Tzakis AG, et al. Orthotopic liver transplantation for alcoholic cirrhosis. JAMA 1988; 260: 2542.
41. Bellamy COC, DiMartini AM, Ruppert K, et al. Liver transplantation for alcoholic cirrhosis: long term follow-up and impact of disease recurrence. Transplantation 2001; 72: 619.
42. DiMartini A, Day N, Dew MA, et al. Alcohol consumption patterns and predictors of use following liver transplantation for alcoholic liver disease. Liver Transpl 2006; 12: 813.
43. Everson G, Bharadhwaj G, House R, et al. Long-term follow-up of patients with alcoholic liver disease who underwent hepatic transplantation. Liver Transpl 1997; 3: 263.
44. Mackie J, Groves K, Hoyle A, et al. Orthotopic liver transplantation for alcoholic liver disease: a retrospective analysis of survival, recidivism, and risk factors predisposing to recidivism. Liver Transpl 2001; 7: 418.
45. Cuadrado A, Fábrega E, Casafont F, et al. Alcohol recidivism impairs long-term patient survival after orthotopic liver transplantation for alcoholic liver disease. Liver Transpl 2005; 11: 420.
46. Lamba S, Nagurka R, Desai KK, et al. Self-reported non-adherence to immune-suppressant therapy in liver transplant recipients: demographic, interpersonal, and intrapersonal factors. Clin Transplant 2012; 26: 328.
47. Faure S, Herrero A, Jung B, et al. Excessive alcohol consumption after liver transplantation impacts on long-term survival, whatever the primary indication. J Hepatol 2012; 57: 306.
48. Schmeding M, Heidenhain C, Neuhaus R, et al. Liver transplantation for alcohol-related cirrhosis: a single centre long-term clinical and histological follow-up. Dig Dis Sci 2011; 56: 236.
49. Lucey MR, Carr K, Beresford TP, et al. Alcohol use after liver transplantation in alcoholics: a clinical cohort follow-up study. Hepatology 1997; 25: 1223.
50. Shawcross DL, O'Grady JG. The 6-month abstinence rule in liver transplantation. Lancet 2010; 376: 216.
51. Robaeys G, Nevens F, Stärkel P, et al. Previous intravenous substance use and outcome of liver transplantation in patients with chronic hepatitis C infection. Transpl Proc 2009; 41: 589.
52. Nickels M, Jain A, Sharma R, et al. Polysubstance abuse in liver transplant patients and its impact on survival outcome. Exp Clin Transplant 2007; 5: 680.
53. Ranney DN, Acker WB, Al-Holou SN, et al. Marijuana use in potential liver transplant candidates. Am J Transplant 2009; 9: 280.
54. Kanchana TP, Kaul V, Manzarbeitia C, et al. Liver transplantation for patients on methadone maintenance. Liver Transpl 2002; 8: 778.
55. Steinman TI, Becker BN, Frost AE, et al. Guidelines for the referral and management of patients eligible for solid organ transplantation. Transplantation 2001; 71: 1189.
56. Orens JB, Estenne M, Arcasoy S, et al. International Guidelines for the Selection of Lung Transplant Candidates: 2006 update? A consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2006; 25: 745.
57. Mehra MR, Kobashigawa J, Starling R, et al. Listing criteria for heart transplantation: International Society for Heart and Lung Transplantation guidelines for the care of cardiac transplant candidatesV2006. J Heart Lung Transplant 2006; 25: 1024.
58. Kasiske BL, Zeier MG, Chapman JR, et al. KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary. Kidney Int 2009; 77: 299.
59. Olbrisch ME, Levenson JL. Psychosocial evaluation of heart transplant candidates: an international survey of process, criteria, and outcomes. J Heart Lung Transplant 1991; 10: 948.
60. Dew MA, DiMartini AF, De Vito Dabbs A, et al. Rates and risk factors for nonadherence to the medical regimen after adult solid organ transplantation. Transplantation 2007; 83: 858.
61. Dew MA, DiMartini AF, Steel J, et al. Meta-analysis of risk for relapse to substance use after transplantation of the liver or other solid organs. Liver Transpl 2008; 14: 159.
62. Evon DM, Burker EJ, Sedway JA, et al. Tobacco and alcohol use in lung transplant candidates and recipients. Clin Transplant 2005; 19: 207.
63. Gueye AS, Chelamcharla M, Baird BC, et al. The association between recipient alcohol dependency and long-term graft and recipient survival. Nephrol Dial Transplant 2007; 22: 891.
64. Machnicki G, Pinsky B, Takemoto S, et al. Predictive ability of pretransplant comorbidities to predict long-term graft loss and death. Am J Transplant 2009; 9: 494.
65. Zelle DM, Agarwal PK, Ramirez JLP, et al. Alcohol consumption, new onset of diabetes after transplantation, and all-cause mortality in renal transplant recipients. Transplantation 2011; 92: 203.
66. Kiechl S, Willeit J, Poewe W, et al. Insulin sensitivity and regular alcohol consumption: large, prospective, cross sectional population study (Bruneck study). BMJ 1996; 313: 1040.
67. Fierz K, Steiger J, Denhaerynck K, et al. Prevalence, severity and correlates of alcohol use in adult renal transplant recipients. Clin Transplant 2006; 20: 171.
68. Sirri L, Potena L, Masetti M, et al. Prevalence of substance-related disorders in heart transplantation candidates. Transplant Proc 2007; 39: 1970.
69. Kelly TM, Donovan JE, Kinnane JM, et al. A comparison of alcohol screening instruments among under-aged drinkers treated in emergency departments. Alcohol Alcohol 2002; 37: 444.
70. Skinner HA. The drug abuse screening test. Addict Behav 1982; 7: 363.
71. Hanrahan JS, Eberly C, Mohanty PK. Substance abuse in heart transplant recipients: a 10-year follow-up study. Prog Transplant 2001; 11: 285.
72. Shapiro PA, Williams DL, Foray AT, et al. Psychosocial evaluation and prediction of compliance problems and morbidity after heart transplantation. Transplantation 1995; 60: 1462.
73. Rice JP, Reich T, Bucholz KK, et al. Comparison of direct interview and family history diagnoses of alcohol dependence. Alcohol Clin Exp Res 1995; 19: 1018.
74. Ewing JA, Rouse BA. Identifying the Hidden Alcoholic. Sydney, Australia. 29th International Congress on Alcohol and Drug Dependence; 1970: 3.
75. Selzer ML. The Michigan Alcoholism Screening Test: the quest for a new diagnostic instrument. Am J Psychiatry 1971; 127: 1653.
76. Saunders JB, Aasland OG, Babor TF, et al. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption-II. Addiction 1993; 88: 791.
77. Lazowski LE, Miller FG, Boye MW, et al. Efficacy of the Substance Abuse Subtle Screening Inventory-3 (SASSI-3) in identifying substance dependence disorders in clinical settings. J Pers Assess 1998; 71: 114.
78. Humeniuk R, Ali R, Babor TF, et al. Validation of the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST). Addiction 2008; 103: 1039.
79. Day E, Best D, Sweeting R, et al. Detecting lifetime alcohol problems in individuals referred for liver transplantation for nonalcoholic liver failure. Liver Transpl 2008; 14: 1609.
80. NHS Blood and Transplant. Advisory group guidelines.
81. Drummond C, Ghodse H. Use of investigations in the diagnosis and management of alcohol use disorders. In: Day E, ed. Clinical Topics in Addiction. London: Royal College of Psychiatrists; 2007: 113.
82. Weinrieb RM, Lucey MR. Treatment of addictive behaviors in liver transplant patients. Liver Transpl 2007; 13: S79.
83. Dimartini A, Dew MA. Monitoring alcohol use on the liver transplant wait list: therapeutic and practical issues. Liver Transpl 2012.
84. Fletcher LM, Kwoh-Gain I, Powell EE, et al. Markers of chronic alcohol ingestion in patients with nonalcoholic steatohepatitis: an aid to diagnosis. Hepatology 1991; 13: 455.
85. Kwoh-Gain I, Fletcher LM, Price J, et al. Desialylated transferrin and mitochondrial aspartate aminotransferase compared as laboratory markers of excessive alcohol consumption. Clin Chem 1990; 36: 841.
86. Bell H, Tallaksen C, Sjahelm T, et al. Serum carbohydrate-deficient transferrin as a marker of alcohol consumption in patients with chronic liver diseases. Alcohol Clin Exp Res 1993; 17: 246.
87. Reynaud M, Schellenberg F, Loisequx-Meunier MN, et al. Objective diagnosis of alcohol abuse: compared values of carbohydratedeficient transferrin (CDT), F-glutamyl transferase (GGT), and mean corpuscular volume (MCV). Alcohol Clin Exp Res 2000; 24: 1414.
88. Chick J, Kreitman N, Plant M. Mean cell volume and gammaglutamyl- transpeptidase as markers of drinking in working men. Lancet 1981; 317: 1249.
89. Anton RF, Dominick C, Bigelow M, et al. Comparison of Bio-Rad% CDT TIA and CDTect as laboratory markers of heavy alcohol use and their relationships with F-glutamyltransferase. Clin Chem 2001; 47: 1769.
90. Conigrave KM, Degenhardt LJ, Whitfield JB, et al. CDT, GGT, and AST as markers of alcohol use: the WHO/ISBRA collaborative project. Alcohol Clin Exp Res 2002; 26: 332.
91. Erim Y, Bottcher M, Dahmen U, et al. Urinary ethyl glucuronide testing detects alcohol consumption in alcoholic liver disease patients awaiting liver transplantation. Liver Transpl 2007; 13: 757.
92. Morini L, Politi L, Acito S, et al. Comparison of ethyl glucuronide in hair with carbohydrate-deficient transferrin in serum as markers of chronic high levels of alcohol consumption. Forensic Sci Int 2009; 188: 140.
93. Kharbouche H, Faouzi M, Sanchez N, et al. Diagnostic performance of ethyl glucuronide in hair for the investigation of alcohol drinking behavior: a comparison with traditional biomarkers. Int J Legal Med 2012; 126: 243.
94. Dufaux B, Agius R, Nadulski T, et al. Comparison of urine and hair testing for drugs of abuse in the control of abstinence in driver's license re-granting. Drug Test Anal 2012; 4: 415.
95. Pragst F, Balikova MA. State of the art in hair analysis for detection of drug and alcohol abuse. Clin Chim Acta 2006; 370: 17.
96. Lendoiro E, Quintela O, de Castro A, et al. Target screening and confirmation of 35 licit and illicit drugs and metabolites in hair by LC-MSMS. Forensic Sci Int 2012; 217: 207.
97. Wurst FM, Wiesbeck GA, Metzger JW, et al. On sensitivity, specificity, and the influence of various parameters on ethyl glucuronide levels in urineVresults from the WHO/ISBRA study. Alcohol Clin Exp Res 2004; 28: 1220.
98. Haller DL, Acosta MC, Lewis D, et al. Hair analysis versus conventional methods of drug testing in substance abusers seeking organ transplantation. Am J Transplant 2010; 10: 1305.
99. Jackson R, Johnson M, Campbell F, et al. Screening and Brief Interventions for Prevention and Early Identification of Alcohol Use Disorders in Adults and Young People. Scharr; 2010.
100. Saitz R, Palfai TP, Cheng DM, et al. Brief intervention for medical inpatients with unhealthy alcohol use: a randomized, controlled trial. Ann Intern Med 2007; 146: 167.
101. Field CA, Caetano R. The effectiveness of brief intervention among injured patients with alcohol dependence: who benefits from brief interventions? Drug Alcohol Depend 2010; 111: 13.
102. Babor TF, McRee BG, Kassebaum PA, et al. Screening, Brief Intervention, and Referral to Treatment (SBIRT): toward a public health approach to the management of substance abuse. Subst Abus 2007; 28: 7.
103. National Coordinating Centre for Mental Health. Drug Misuse: Psychosocial Interventions. London: British Psychological Society & The Royal College of Psychiatrists; 2008.
104. Weinrieb RM, Van Horn DHA, Lynch KG, et al. A randomized, controlled study of treatment for alcohol dependence in patients awaiting liver transplantation. Liver Transpl 2011; 17: 539.
105. Vaillant GE. The natural history of alcoholism and its relationship to liver transplantation. Liver Transpl Surg 1997; 3: 304.
106. Connock M, Juarez-Garcia A, Jowett S, et al. Methadone and Buprenorphine for the Management of Opioid Dependence: A Systematic Review and Economic Evaluation. Gray Publishing; 2007.
107. Stitzer ML, Vandrey R. Contingency management: utility in the treatment of drug abuse disorders. Clin Pharmacol Ther 2008; 83: 644.
108. Day E, Best D, Sweeting R, et al. Predictors of psychological morbidity in liver transplant assessment candidates: is alcohol abuse or dependence a factor? Transpl Int 2009; 22: 606.
109. Dew MA, Kormos RL, Roth LH, et al. Early post-transplant medical compliance and mental health predict physical morbidity and mortality one to three years after heart transplantation. J Heart Lung Transplant 1999; 18: 549.
110. Zipfel S, Schneider A,Wild B, et al. Effect of depressive symptoms on survival after heart transplantation. Psychosom Med 2002; 64: 740.
111. Iwasaki K. Metabolism of tacrolimus (FK506) and recent topics in clinical pharmacokinetics. Drug Metab Pharmacokinet 2007; 22: 328.
112. GuyattGH,Oxman AD, VistGE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008; 336: 924.
113. Guyatt GH, Oxman AD, Schunemann HJ, et al. GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. J Clin Epidemiol 2011; 64: 380.
114. Mann K, Lehert P, Morgan MY. The efficacy of acamprosate in the maintenance of abstinence in alcohol-dependent individuals: results of a meta-analysis. Alcohol Clin Exp Res 2004; 28: 51.
115. Björnsson E, Olsson J, Rydell A, et al. Long-term follow-up of patients with alcoholic liver disease after liver transplantation in Sweden: impact of structured management on recidivism. Scand J Gastroenterol 2005; 40: 206.
116. Streeton C,Whelan G. Naltrexone, a relapse prevention maintenance treatment of alcohol dependence: a meta-analysis of randomized controlled trials. Alcohol Alcohol 2001; 36: 544.
117. Addolorato G, Leggio L, Ferrulli A, et al. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. Lancet 2007; 370: 1915.
118. Butkus DE, Dottes AL,Meydrech EF, et al. Effect of poverty and other socioeconomic variables on renal allograft survival. Transplantation 2001; 72: 261.